Antibody Drug Conjugates Market, 2030 - Type of Payload, Type of Linker, Target Indications, Target Antigens, Technology Providers, Key Geographies - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Nov 5, 2019--
The “Antibody Drug Conjugates Market (5th Edition), 2019-2030” report has been added to ResearchAndMarkets.com’s offering.
With six approved and marketed drugs, namely POLIVY (2019), LUMOXITI (2018), BESPONSA (2017), MYLOTARG (2017, reapproval), KADCYLA (2013) and ADCETRIS (2011), antibody drug conjugates (ADCs) have become recognized as a potent class of targeted therapeutic agents catering to oncology and hematological diseases markets. The success of such conjugated products can be attributed to their ability to effectively identify and eliminate disease-associated cells / pathogens, while limiting off-target toxicities. Presently, ADCs are considered a part of mainstream healthcare regimens, having generated significant enthusiasm within the medical science community across the world.
The growing popularity and therapeutic potential of ADCs can also be correlated with an exponential increase in the number of patents that have been filed / granted; the cumulative patent count has increased from 1,395 in 2009 to over 16,500 in the first half of 2019. With more than 200 ADCs in clinical / preclinical stages of development, the industry is gradually shifting from relying on conventional technologies to newer and more robust approaches to conjugate such complex biomolecules. Over the years, a number of well-funded start-ups / small companies, offering novel conjugation technologies, more potent warheads and advanced linker technologies, have been established. In fact, multiple licensing agreements / collaborations have been inked in the past few years between drug developers and technology providers to advance the development of pipeline ADC candidates.
Using ADCs in combination with other drug / therapy classes is an emerging concept and multiple companies are evaluating their proprietary ADC candidates in combination with other established therapeutic classes, such as immune checkpoint inhibitors, epigenetic modulators and monoclonal antibodies. In addition, several other companies have introduced certain novel types of conjugated drug molecules; example of such companies include Bicycle Therapeutics (bicycle drug conjugate), BlinkBio (tunable drug conjugates), Cellectar Biosciences (phospholipid drug conjugate), Centrose (extracellular drug conjugate), Esperance Pharmaceuticals (peptide conjugate) and Nordic Nanovector (radionucleotide conjugate). We expect the ADC therapeutics market to grow at a healthy rate in the mid to long-term, driven by the introduction of new combination therapies involving ADCs, innovative ADC development and conjugation technologies, applications beyond oncology and the expansion of existing marketing authorizations to newer geographies across the world.
Scope of the Report
The Antibody Drug Conjugates Market (5th Edition), 2019-2030′ report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapeutics over the next decade. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain.
One of the key objectives of the report was to estimate the existing market size and identify potential growth opportunities for ADCs, over the coming decade. Based on several parameters, such as target consumer segments, region-specific adoption rates and expected prices of such products, we have provided an informed estimate on the likely evolution of the market for the period 2019-2030. The report includes potential sales forecasts of ADCs that are currently marketed or are in late stages of development.
Additionally, it provides forecasts of the overall ADCs market, wherein the current and upcoming opportunity is segmented across
To account for the uncertainties associated with the development of these novel therapeutics and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.
In addition to other elements, the study includes:
For more information about this report visit https://www.researchandmarkets.com/r/k5icki
View source version on businesswire.com:https://www.businesswire.com/news/home/20191105005941/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH ONCOLOGY
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 11/05/2019 12:23 PM/DISC: 11/05/2019 12:23 PM